Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Riad Sherif M.B.A., M.D. | CEO & Director | -- | -- | 1968 |
| Ms. Sylvia Cheung | Chief Financial Officer | -- | -- | 1975 |
| Ms. Gudrun Bachmann Ph.D. | Chief Technology Officer | -- | -- | -- |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. Daniel S. Char J.D. | Chief Legal Officer | -- | -- | 1961 |
| Ms. Virginia R. Dean | Chief Human Resources Officer | -- | -- | 1967 |
| Mr. Páll Ragnar Jóhannesson | Chief Business Officer | -- | -- | 1982 |
| Ms. Rebecca Weil | Chief Commercial Officer | -- | -- | -- |
| Dr. Snehal Shah Pharm.D. | President of Research & Development | -- | -- | -- |
| Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer | -- | -- | -- |
Oculis Holding AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 36
Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Corporate Governance
Upcoming Events
November 7, 2024 at 9:00 AM UTC
Oculis Holding AG Earnings Date
Recent Events
September 4, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
April 1, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission